Last reviewed · How we verify
NCT06136325
Treatment of Anal Fistulas With Obsidian RFT®
trial testing Obsidian RFP anal fistula surgery in Anal Fistula in 18 participants. Completed in 27 October 2023.
31 December 2022
Quick facts
| Lead sponsor | Medical University of Vienna |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 18 |
| Start date | 17 January 2018 |
| Primary completion | 31 December 2022 |
| Estimated completion | 27 October 2023 |
| Sites | 1 location across Austria |
Drugs / interventions tested
- Obsidian RFP anal fistula surgery
Conditions studied
- Anal Fistula — all drugs for Anal Fistula →
- Minimal Invasive Surgery — all drugs for Minimal Invasive Surgery →
- Platelet-rich Fibrin Foam — all drugs for Platelet-rich Fibrin Foam →
Sponsor
Medical University of Vienna
Who can join
Adults 18 to 99, any sex, with Anal Fistula or Minimal Invasive Surgery. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The study conducted a retrospective analysis from January 2018 to December 2022 on patients who received anal fistula closure with Obsidian RTF® at the Department of General Surgery, Medical University of Vienna.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Treatment of anal fistulas with Obsidian RFT<sup>®</sup>: just another autologous compound platelet-rich fibrin foam?
Dawoud C, Girgis K, Stift A, Harpain F, et al · · 2024 · cited 2× · PMID 39095560 · DOI 10.1007/s10151-024-02968-6
Verify or expand the search:
- PubMed search for NCT06136325
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Anal Fistula
Currently open trials in the same condition.
- NCT07477496 — Recurrence and Anal Fistula Patient Reported Outcomes Trial · recruiting
- NCT07081373 — Study on Repeat Liposomal Bupivacaine for Post-Surgery Pain in Anal Fistula Patients. · NA · recruiting
- NCT06803550 — Effect of Enhanced Recovery After Surgery for Benign Anorectal Conditions · NA · recruiting
- NCT06303752 — Tissue Therapy of Transsphincteric Anal Fistula · Phase 1, PHASE2 · recruiting
- NCT05641844 — A Double Blind, Randomized Controlled Study, Evaluating the Safety and Efficacy of RD2 Ver.02 For the Management of Anal · NA · recruiting
Other Medical University of Vienna trials
Trials by the same sponsor.
- NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
- NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
- NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
- NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
- NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06136325 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
- Last refreshed: 18 November 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06136325.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing